5/15/2019 6:55:34 AM
Wedbush Cuts bluebird bio Inc. (BLUE) To Neutral From Outperform With $131 Down From $166 Price Target
2/11/2019 6:36:01 AM
Bluebird Bio Names Chip Baird CFO
1/7/2019 8:13:34 AM
Bluebird Bio And Inhibrx Collaborate To Research, Develop And Commercialize CAR T Cell Immunotherapies
12/3/2018 9:32:36 PM
Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Sickle Cell Disease
12/3/2018 9:32:23 PM
Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Transfusion Dependent ?-Thalassemia
12/2/2018 7:33:57 PM
Bluebird Bio, Celgene Present Initial Data From Phase 1 Study Of Anti-BCMA CAR T Cell Therapy Bb21217 In Relapsed/RMM
11/27/2018 7:32:55 AM
Celgene And Bluebird Bio Complete Enrollment For KarMMa Pivotal Tudy Of Bb2121
11/5/2018 6:48:52 AM
Wedbush Is Increasing bluebird bio Inc. (BLUE) FY18 Rev. Estimate To 46.3 M From 43.4 M
11/5/2018 6:48:41 AM
Wedbush Is Increasing bluebird bio Inc. (BLUE) Q4 18 Rev. Estimate To 10.9 M From 9.9 M
11/5/2018 6:48:04 AM
Wedbush Is Increasing bluebird bio Inc. (BLUE) FY18 Estimate To -10.74 From -11.52
11/5/2018 6:47:42 AM
Wedbush Is Increasing bluebird bio Inc. (BLUE) Q4 18 Estimate To -2.80 From -3.07
10/5/2018 5:03:05 AM
Bluebird Bio Reports EMA’s Acceptance Of Marketing Authorization Application For LentiGlobin
9/5/2018 6:12:06 AM
Bluebird Bio Reports Updated Results From Phase 2/3 Starbeam Study (ALD-102) Of Lenti-D Gene Therapy
8/23/2018 6:35:28 AM
Bluebird Bio, Gritstone Oncology Collaborate To Develop Products For Treatment Of Cancer Using Cell Therapy
8/6/2018 6:32:25 AM
Bluebird Bio, Regeneron Partner To Apply Technology Platforms To Develop Novel Cell Therapies For Cancer
8/2/2018 6:35:53 AM
Bluebird Bio Q2 Loss Per Share $2.91 Vs Loss $1.73 Last Year
7/23/2018 4:03:18 PM
Bluebird Bio Announces Proposed Public Offering Of Common Stock